Skip to Content


Medically reviewed by Last updated on June 26, 2020.

Scientific Name(s): Pausinystalia yohimbe (K. Schum.) Pierre ex Beille.
Common Name(s): Aphrodien, Aphrodyne, Johimbi, Yocon, Yohimbe, Yohimbehe, Yohimbine

Clinical Overview


Yohimbine has been used primarily in the treatment of sexual dysfunction, weight (body fat) loss, and xerostomia (dry mouth). It has also been used in studies investigating disorders including autonomic failure and orthostatic hypotension. Effects on the CNS including reductions in fear and increased impulsivity have been reported.


Yohimbine 6 mg given 3 times a day has been used in xerostomia trials. A mean dose of 0.4 mg/kg body weight or 30 mg daily, and a maximum of 50 mg, has been used in erectile dysfunction studies. In studies investigating effects on body mass, yohimbine 20 mg daily has been used.


This drug should not be used in the presence of renal or hepatic dysfunction. Contraindicated in pregnancy.


Do not use during pregnancy or lactation.


None well documented.

Adverse Reactions

Clinical trials report few serious adverse reactions. There are case reports of rash, lupus-like syndrome, bronchospasm, severe hypotension, dysrhythmia, heart failure, and death. Increased anxiety, irritability, and excitability have also been reported. Animal studies suggest yohimbine may increase motor activity and seizures at higher dosages. Yohimbe may precipitate psychoses in predisposed individuals.


Information is limited.

Scientific Family

  • Rubiaceae


Yohimbe (P. yohimbe) is a tall evergreen tree that grows throughout the African nations of Cameroon, Gabon, and the Democratic Republic of the Congo.1 A synonym for yohimbine is Corynanthe johimbe.


The bark of the West African yohimbe tree is rich in the alkaloid yohimbine, and the crude bark has been used traditionally as an aphrodisiac. The bark has also been smoked as a hallucinogen and used in traditional medicine to treat angina and hypertension. The drug has been investigated for the treatment of organic and psychogenic erectile dysfunction.2


Authentic yohimbe bark may contain up to 6% total alkaloids, of which 10% to 15% is yohimbine. Other minor indole alkaloids include corynantheidine, beta-yohimbine, pseudoyohimbine, rauwolscine, coryanthine, and allo-yohimbine.3 A comparison of chromatograms of authentic P. yohimbe bark extracts with those of commercial products containing yohimbine found that many products contained measurable quantities of the alkaloid yohimbine, but had very little of the other alkaloids previously reported in the species. Concentrations of yohimbine in commercial products ranged from less than 0.1 to 489 parts per million (ppm) compared with 7,089 ppm in the authentic material.4 The alkaloid yohimbine also is obtained from Aspidosperma quebracho-blanco and Rauwolfia serpentina.

The salt yohimbine hydrochloride has been used in clinical studies, while the free base is usually found in yohimbe extract or bark. Qualitative and quantitative analyses of commercial products and yohimbe bark have been undertaken using high performance liquid chromatography, nonaqueous capillary electrophoresis, and gas chromatography-mass spectrometry.3, 5

Uses and Pharmacology

Body mass/muscle mass

Animal data

The availability of clinical trial data renders findings from recent animal studies largely irrelevant.

Clinical data

A systematic review of 3 high-quality clinical trials using yohimbine to reduce body weight found conflicting results and could not conclude that yohimbine use is effective.1 Studies evaluating the effect on body and muscle mass have also been inconclusive.6, 7 In a study among athletes, yohimbine 20 mg daily for 21 days had no effect on body mass or muscle mass, but did decrease body fat. No effect on exercise performance was found.7


Animal data

Studies in rodents have shown effects on the CNS, including reduced fear, with yohimbine administration.8

Clinical data

In a study conducted in 40 patients with social anxiety disorder, the use of yohimbine improved self-reported measures, but not clinician-rated outcomes.8 Similarly, in a small trial (n=24) improvements in claustrophobic symptoms were reported with yohimbine administration.9

Among healthy volunteers in another study, however, yohimbine increased panic symptoms10 A study evaluating the effect of yohimbine on impulsivity found increased risk for impulsive behaviour in healthy volunteers,11 while a further trial reported increased craving following cocaine-cue presentation,12 and drug-seeking behaviour13 among dependent individuals.

Erectile dysfunction

Animal data

Yohimbine may act by adrenergic blockade of alpha-2-adrenergic receptors in the corpus cavernosum and centrally in the serotonergic system. It has been investigated for use in treatment of sexual dysfunction.14

Clinical data

The American Urological Association (AUA) guidelines on the management of erectile dysfunction (2005) states that yohimbine is not recommended for the treatment of erectile dysfunction based on review of data and panel consensus.15

A number of meta-analyses published before the above-mentioned AUA guidelines were conducted on older clinical trials, all concluding that yohimbine was more effective than placebo in treating erectile dysfunction in most, but not all, men.14, 16, 17, 18 No serious adverse events were reported in the trials included in the meta-analyses. Limitations of the trials have been noted and include a lack of statistical power, reporting bias, and a strong placebo effect.14, 18

A more recent open-label study found yohimbine to be effective in managing anorgasmia (orgasmic dysfunction).19 Dosing was initiated at 20 mg, with 5 mg escalations to a maximum of 50 mg. A mean dose of 0.4 mg/kg body weight was determined.19 The development of tolerance was suggested by one reviewer.14

Syncope/orthostatic hypotension

Animal data

The availability of clinical trial data renders findings from recent animal studies largely irrelevant.

Clinical data

Yohimbine dilates blood vessels, thereby lowering blood pressure; however, its use as an antihypertensive agent has been abandoned.14 As a selective alpha-2-adrenergic antagonist, yohimbine has been used to test baroreflex-mediated bradycardia and the contribution of endogenous alpha-2-adrenergic blockade to baroreflex regulation in human studies.20, 21, 22, 23 The use of yohimbine in the management of syncope or orthostatic hypotension has, however, not been conclusively established.

Yohimbine increased norepinephrine, epinephrine, muscle sympathetic nerve activity, blood pressure, and heart rate in neurally-mediated syncope patients compared with baseline.20, 24 Other studies did not report increases in heart rate or blood pressure.21, 22 Yohimbine has been used in a study to evaluate symptoms of autonomic failure in patients with Parkinson disease, approximately 40% of whom exhibit orthostatic hypotension.25 Yohimbine was more effective than pyridostigmine at improving orthostatic hypotension in a study population that included multiple system atrophy, pure autonomic failure, and Parkinson disease.26

Xerostomia (dry mouth)

In animal studies and limited human trials, yohimbine increased salivary flow and countered the effects of drugs such as tricyclic antidepressants or neuroleptics that cause xerostomia.27, 28

Other uses

Yohimbine has been investigated for treatment of posttraumatic stress disorder,29 panic disorder,30 emotional stress response,31 pteromerhanophobia (fear of flying),32 and cancer.33


Yohimbine 6 mg 3 times a day has been used in xerostomia trials.28 A mean dose of 0.4 mg/kg body weight or 30 mg daily, and a maximum of 50 mg, has been used in erectile dysfunction studies.17, 19 The development of tolerance has been suggested by one reviewer.14 In studies investigating effects on body mass, yohimbine 20 mg daily has been used.7

Pregnancy / Lactation

Do not use during pregnancy or lactation.


Antianxiety agents: Yohimbine may diminish the therapeutic effect of antianxiety agents. Monitor therapy.34, 35, 36, 37

Antihypertensive agents: Yohimbine may diminish the antihypertensive effect of antihypertensives. Monitor therapy.34

Iobenguane radiopharmaceutical products: Yohimbine may diminish the therapeutic effect of iobenguane radiopharmaceutical products. Avoid combination.38, 39

Tricyclic antidepressants: Tricyclic antidepressants may increase the serum concentration of yohimbine. Monitor therapy.40, 41, 42, 43, 44, 45

Adverse Reactions

Clinical trials report few serious adverse events.14, 16, 46 Case reports exist of rash, lupus-like syndrome, bronchospasm, arrhythmias, and death associated with yohimbine consumption.47, 48, 49, 50 Increased anxiety, irritability, and excitability have also been reported.10, 51

Animal studies suggest yohimbine may increase motor activity and seizures at higher dosages, may cause CNS stimulation and paralysis, and may precipitate psychoses in predisposed individuals. Signs of yohimbine toxicity include severe hypotension, dysrhythmia, heart failure, and death.51

In the 2016 Scientific Statement by the American Heart Association regarding drugs that may cause or exacerbate heart failure, yohimbine has been recognized as a product with possibly harmful cardiovascular effects, such as hypertension due to increased norepinephrine via alpha2-adrenergic receptor antagonism, and may be harmful in patients with heart failure. The guideline statement noted that naturoceuticals are not recommended for the management of heart failure symptoms or for the secondary prevention of cardiovascular events, and that nutritional supplements are not recommended for the treatment of heart failure [Low-quality; Limited].52


The reproductive toxicology of yohimbine was investigated in rats. At high dosages, increases in the weight of seminal vesicles was noted, as well as decreases in sperm count and motility and increases in sperm abnormalities.53

Index Terms

  • Corynanthe johimbe


1. Pittler MH, Ernst E. Dietary supplements for body-weight reduction: a systematic review. Am J Clin Nutr. 2004;79(4):529-536.15051593
2. Reid K, Surridge DH, Morales A, et al. Double-blind trial of yohimbine in treatment of psychogenic impotence. Lancet. 1987;2(8556):421-423.2887726
3. Zanolari B, Ndjoko K, Ioset JR, Marston A, Hostettmann K. Qualitative and quantitative determination of yohimbine in authentic yohimbe bark and in commercial aphrodisiacs by HPLC-UV-API/MS methods. Phytochem Anal. 2003;14(4):193-201.12892413
4. Betz JM, White KD, der Marderosian AH. Gas chromatographic determination of yohimbine in commercial yohimbe products. J AOAC Int. 1995;78(5):1189-1194.7549534
5. Chen Q, Li P, Zhang Z, Li K, Liu J, Li Q. Analysis of yohimbine alkaloid from Pausinystalia yohimbe by non-aqueous capillary electrophoresis and gas chromatography-mass spectrometry. J Sep Sci. 2008;31(12):2211-2218.18615826
6. Bucci LR. Selected herbals and human exercise performance. Am J Clin Nutr. 2000;72(2 suppl):624S-636S.10919969
7. Ostojic SM. Yohimbine: the effects on body composition and exercise performance in soccer players. Res Sports Med. 2006;14(4):289-299.17214405
8. Smits JA, Rosenfield D, Davis ML, et al. Yohimbine enhancement of exposure therapy for social anxiety disorder: a randomized controlled trial. Biol Psychiatry. 2014;75(11):840-846.24237691
9. Powers MB, Smits JA, Otto MW, Sanders C, Emmelkamp PM. Facilitation of fear extinction in phobic participants with a novel cognitive enhancer: a randomized placebo controlled trial of yohimbine augmentation. J Anxiety Disord. 2009;23(3):350-356.19223151
10. Vasa RA, Pine DS, Masten CL, et al. Effects of yohimbine and hydrocortisone on panic symptoms, autonomic responses, and attention to threat in healthy adults. Psychopharmacology (Berl). 2009;204(3):445-455.19266185
11. Swann AC, Lijffijt M, Lane SD, et al. Norepinephrine and impulsivity: effects of acute yohimbine. Psychopharmacology (Berl). 2013;229(1):83-94.23559222
12. Moran-Santa Maria MM, McRae-Clark A, Baker NL, Ramakrishnan V, Brady KT. Yohimbine administration and cue-reactivity in cocaine-dependent individuals. Psychopharmacology (Berl). 2014;231(21):4157-4165.24710621
13. Greenwald MK, Lundahl LH, Steinmiller CL. Yohimbine increases opioid-seeking behavior in heroin-dependent, buprenorphine-maintained individuals. Psychopharmacology (Berl). 2013;225(4):811-824.23161001
14. Morales A. Yohimbine in erectile dysfunction: the facts. Int J Impot Res. 2000;12(suppl 1):S70-S74.10845767
15. Erectile Dysfunction Guideline Update Panel. Erectile Dysfunction. American Urological Association. 2011.
16. Ernst E, Pittler MH. Yohimbine for erectile dysfunction: a systematic review and meta-analysis of randomized clinical trials. J Urol. 1998;159(2):433-436.9649257
17. Vogt HJ, Brandl P, Kockott G, et al. Double-blind, placebo-controlled safety and efficacy trial with yohimbine hydrochloride in the treatment of nonorganic erectile dysfunction. Int J Impot Res. 1997;9(3):155-161.9315493
18. Carey MP, Johnson BT. Effectiveness of yohimbine in the treatment of erectile disorder: four meta-analytic integrations. Arch Sex Behav. 1996;25(4):341-360.8836468
19. Adeniyi AA, Brindley GS, Pryor JP, Ralph DJ. Yohimbine in the treatment of orgasmic dysfunction. Asian J Androl. 2007;9(3):403-407.17486282
20. Tank J, Heusser K, Diedrich A, Brychta RJ, Luft FC, Jordan J. Yohimbine attenuates baroreflex-mediated bradycardia in humans. Hypertension. 2007;50(5):899-90317875819
21. Wray DW, Raven PB, Sander M. Diminished baroreflex-induced vasoconstriction following alpha-2 adrenergic receptor blockade in humans. Auton Neurosci. 2008;138(1-2):114-117.18054844
22. Bharucha AE, Charkoudian N, Andrews CN, et al. Effects of glucagon-like peptide-1, yohimbine, and nitrergic modulation on sympathetic and parasympathetic activity in humans. Am J Physiol Regul Integr Comp Physiol. 2008;295(3):R874-R880.18596108
23. Kaya S, Kolodjaschna J, Berisha F, et al. Effect of the α(2)-adrenoceptor antagonist yohimbine on vascular regulation of the middle cerebral artery and the ophthalmic artery in healthy subjects. Microvasc Res. 2011;81(1):117-122.20934440
24. Mosqueda-Garcia R, Fernandez-Violante R, Tank J, Snell M, Cunningham G, Furlan R. Yohimbine in neurally mediated syncope. Pathophysiological implications. J Clin Invest. 1998;102(10):1824-1830.9819368
25. Sharabi Y, Imrich R, Holmes C, Pechnik S, Goldstein DS. Generalized and neurotransmitter-selective noradrenergic denervation in Parkinson's disease with orthostatic hypotension. Mov Disord. 2008;23(12):1725-1732.18661549
26. Shibao C, Okamoto LE, Gamboa A, et al. Comparative efficacy of yohimbine against pyridostigmine for the treatment of orthostatic hypotension in autonomic failure. Hypertension. 2010;56(5):847-851.20837887
27. Abebe W. An overview of herbal supplement utilization with particular emphasis on possible interactions with dental drugs and oral manifestations. J Dent Hyg. 2003;77(1):37-46.12704968
28. Bagheri H, Schmitt L, Berlan M, Montastruc JL. A comparative study of the effects of yohimbine and anetholtrithione on salivary secretion in depressed patients treated with psychotropic drugs. Eur J Clin Pharmacol. 1997;52(5):339-342.9272401
29. Morgan CA 3rd, Grillon C, Southwick SM, et al. Yohimbine facilitated acoustic startle in combat veterans with post-traumatic stress disorder. Psychopharmacology (Berl). 1995;117(4):466-471.7604149
30. Kaplan JS, Arnkoff DB, Glass CR, et al. Avoidant coping in panic disorder: a yohimbine biological challenge study. Anxiety Stress Coping. 2012;25(4):425-442.2186420410.1080/10615806.2011.609587
31. Sommer M, Braumann M, Althoff T, et al. Psychological and neuroendocrine responses to social stress and to the administration of the alpha-2-receptor antagonist, yohimbine, in highly trained endurance athletes in comparison to untrained healthy controls. Pharmacopsychiatry. 2011;44(4):129-134.21710402
32. Meyerbroeker K, Powers MB, van Stegeren A, Emmelkamp PM. Does yohimbine hydrochloride facilitate fear extinction in virtual reality treatment of fear of flying? A randomized placebo-controlled trial. Psychother Psychosom. 2012;81(1):29-37.22116378
33. Shen SG, Zhang D, Hu HT, Li JH, Wang Z, Ma QY. Effects of alpha-adrenoreceptor antagonists on apoptosis and proliferation of pancreatic cancer cells in vitro. World J Gastroenterol. 2008;14(15):2358-2363.18416462
34. Tam SW, Worcel M, Wyllie M. Yohimbine: a clinical review. Pharmacol Ther. 2001;91:215-243.11744068
35. Mattila M, Seppala T, Mattila MJ. Anxiogenic effect of yohimbine in healthy subjects: comparison with caffeine and antagonism by clonidine and diazepam. Int Clin Psychopharmacol. 1988;3:215-229.
36. Charney DS, Breier A, Jatlow PI, et al. Behavioral, biochemical, and blood pressure responses to alprazolam in healthy subjects: interactions with yohimbine. Psychopharmacology (Berl). 1986;88:133-140.
37. Charney DS, Heninger GR,Redmond DE, Jr. Yohimbine induced anxiety and increased noradrenergic function in humans: effects of diazepam and clonidine. Life Sci. 1983;33:19-29.
38. AdreView (iobenguane I 123) [prescribing information]. Arlington Heights, IL: GE Healthcare; March 2013.
39. Azedra (iobenguane I 131) [prescribing information]. New York, NY: Progenics Pharmaceuticals Inc; July 2018.
40. Bagheri H, Picault P, Schmitt L, et al. Pharmacokinetic study of yohimbine and its pharmacodynamic effects on salivary secretion in patients treated with tricyclic antidepressants. Br J Clin Pharmacol.1994;37:93-96.8148228
41. Goldstein DS, Eisenhofer G, Stull R, et al. Plasma dihydroxyphenylglycol and the intraneuronal disposition of norepinephrine in humans. J Clin Invest. 1988;81:213-20.3335637
42. Charney DS, Price LH,Heninger GR. Desipramine-yohimbine combination treatment of refractory depression. implications for the beta-adrenergic receptor hypothesis of antidepressant action. Arch Gen Psychiatry. 1986;43:1155-1161.3022664
43. Laakmann G, Wittmann M, Schoen HW, et al. Effects of receptor blockers (methysergide, propranolol, phentolamine, yohimbine and prazosin) on desimipramine-induced pituitary hormone stimulation in humans--III. Hypothalamo-pituitary-adrenocortical axis. Psychoneuroendocrinology. 1986;11:475-489.3031718
44. Laakmann G, Zygan K, Schoen HW, et al. Effect of receptor blockers (methysergide, propranolol, phentolamine, yohimbine and prazosin) on desimipramine-induced pituitary hormone stimulation in humans--I. growth hormone. Psychoneuroendocrinology. 1986;11:447-461.3031716
45. Hoffman BB, Lefkowitz RJ. Catecholamines, sympathomimetic drugs, and adrenergic receptor antagonists. In: Hardman JG, Limbird LE, Molinoff PB, et al, eds. Goodman and Gilman'sThe Pharmacologic Basis of Therapeutics. 9th Ed. The McGraw-Hill Companies, Inc; 1996, pp 199-248.
46. Pittler MH, Schmidt K, Ernst E. Adverse events of herbal food supplements for body weight reduction: systematic review. Obes Rev. 2005;6(2):93-111.15836459
47. Sandler B, Aronson P. Yohimbine-induced cutaneous drug eruption, progressive renal failure, and lupus-like syndrome. Urology. 1993;41(4):343-345.8470320
48. Landis E, Shore E. Yohimbine-induced bronchospasm. Chest. 1989;96(6):1424.2582853
49. Dangerous supplements: still at large. Consum Rep. 2004;69(5):12-17.15104077
50. Risky pills: supplements to avoid. Consum Rep. 2008;73(1):46-47.18488285
51. National Standard: the authority on integrative medicine [Internet]. Cambridge (MA): Natural Standard; 2005. Yohimbe bark extract (Pausinystalia yohimbe Pierre ex Beille Rubiaceae); [updated 2005 Sep 1; cited 2009 Nov 12]; [about 10 p.]
52. Page RL 2nd, O'Bryant CL, Cheng D, et al; American Heart Association Clinical Pharmacology and Heart Failure and Transplantation Committees of the Council on Clinical Cardiology; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular and Stroke Nursing; and Council on Quality of Care and Outcomes Research. Drugs That May Cause or Exacerbate Heart Failure: A Scientific Statement From the American Heart Association. Circulation. 2016;134(6):e32-69.27400984
53. Al-Majed AA, Al-Yahya AA, Al-Bekairi AM, Al-Shabanah OA, Qureshi S. Reproductive, cytological and biochemical toxicity of Yohimbe in male Swiss albino mice. Asian J Androl. 2006;8(4):469-476.16763724


This information relates to an herbal, vitamin, mineral or other dietary supplement. This product has not been reviewed by the FDA to determine whether it is safe or effective and is not subject to the quality standards and safety information collection standards that are applicable to most prescription drugs. This information should not be used to decide whether or not to take this product. This information does not endorse this product as safe, effective, or approved for treating any patient or health condition. This is only a brief summary of general information about this product. It does NOT include all information about the possible uses, directions, warnings, precautions, interactions, adverse effects, or risks that may apply to this product. This information is not specific medical advice and does not replace information you receive from your health care provider. You should talk with your health care provider for complete information about the risks and benefits of using this product.

This product may adversely interact with certain health and medical conditions, other prescription and over-the-counter drugs, foods, or other dietary supplements. This product may be unsafe when used before surgery or other medical procedures. It is important to fully inform your doctor about the herbal, vitamins, mineral or any other supplements you are taking before any kind of surgery or medical procedure. With the exception of certain products that are generally recognized as safe in normal quantities, including use of folic acid and prenatal vitamins during pregnancy, this product has not been sufficiently studied to determine whether it is safe to use during pregnancy or nursing or by persons younger than 2 years of age.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.